{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:29:55Z","timestamp":1790810995505,"version":"4.1.0"},"reference-count":81,"publisher":"American Association for Cancer Research (AACR)","issue":"10","funder":[{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Upenn TAPITMAT grant"},{"name":"National Cancer Institute","award":["NCI 1K99CA212302"],"award-info":[{"award-number":["NCI 1K99CA212302"]}]},{"name":"National Cancer Institute","award":["R00CA212302"],"award-info":[{"award-number":["R00CA212302"]}]},{"DOI":"10.13039\/100012200","name":"Laffey-McHugh Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012200","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014547","name":"Parker Institute for Cancer Immunotherapy","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014547","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Berman and Maguire Funds for Lymphoma Research at Penn"},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chimeric antigen receptor T-cell (CART) immunotherapy led to unprecedented responses in patients with refractory\/relapsed B-cell non-Hodgkin lymphoma (NHL); nevertheless, two thirds of patients experience treatment failure. Resistance to apoptosis is a key feature of cancer cells, and it is associated with treatment failure. In 87 patients with NHL treated with anti-CD19 CART, we found that chromosomal alteration of B-cell lymphoma 2 (BCL-2), a critical antiapoptotic regulator, in lymphoma cells was associated with reduced survival. Therefore, we combined CART19 with the FDA-approved BCL-2 inhibitor venetoclax and demonstrated in vivo synergy in venetoclax-sensitive NHL. However, higher venetoclax doses needed for venetoclax-resistant lymphomas resulted in CART toxicity. To overcome this limitation, we developed venetoclax-resistant CART by overexpressing mutated BCL-2(F104L), which is not recognized by venetoclax. Notably, BCL-2(F104L)-CART19 synergized with venetoclax in multiple lymphoma xenograft models. Furthermore, we uncovered that BCL-2 overexpression in T cells intrinsically enhanced CART antitumor activity in preclinical models and in patients by prolonging CART persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study highlights the role of BCL-2 in resistance to CART immunotherapy for cancer and introduces a novel concept for combination therapies\u2014the engineering of CART cells to make them resistant to proapoptotic small molecules, thereby enhancing the therapeutic index of these combination therapies.<\/jats:p>\n                    <jats:p>This article is highlighted in the In This Issue feature, p. 2221<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-21-1026","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:25:50Z","timestamp":1659090350000},"page":"2372-2391","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer"],"prefix":"10.1158","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8099-628X","authenticated-orcid":false,"given":"Yong Gu","family":"Lee","sequence":"first","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"3College of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9615-1935","authenticated-orcid":false,"given":"Puneeth","family":"Guruprasad","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-3579","authenticated-orcid":false,"given":"Guido","family":"Ghilardi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-0929","authenticated-orcid":false,"given":"Raymone","family":"Pajarillo","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-3349","authenticated-orcid":false,"given":"Christopher Tor","family":"Sauter","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8366-1928","authenticated-orcid":false,"given":"Ruchi","family":"Patel","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7384-7363","authenticated-orcid":false,"given":"Hatcher J.","family":"Ballard","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5360-8800","authenticated-orcid":false,"given":"Seok Jae","family":"Hong","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-2358","authenticated-orcid":false,"given":"Inkook","family":"Chun","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5765-8052","authenticated-orcid":false,"given":"Nicholas","family":"Yang","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-9948","authenticated-orcid":false,"given":"Kimberly V.","family":"Amelsberg","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9041-0828","authenticated-orcid":false,"given":"Katherine D.","family":"Cummins","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-7065","authenticated-orcid":false,"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7778","authenticated-orcid":false,"given":"Saar","family":"Gill","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8895-1625","authenticated-orcid":false,"given":"Elise A.","family":"Chong","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3885-870X","authenticated-orcid":false,"given":"Khrystyna","family":"North","sequence":"additional","affiliation":[{"name":"5NanoString Technologies Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-4282","authenticated-orcid":false,"given":"Sarah E.","family":"Church","sequence":"additional","affiliation":[{"name":"5NanoString Technologies Inc., Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8993","authenticated-orcid":false,"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9555-7623","authenticated-orcid":false,"given":"Wan-Jung","family":"Chang","sequence":"additional","affiliation":[{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-1962","authenticated-orcid":false,"given":"Simon F.","family":"Lacey","sequence":"additional","affiliation":[{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7707-1232","authenticated-orcid":false,"given":"Xueqing Maggie","family":"Lu","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5608-0615","authenticated-orcid":false,"given":"Yunlin","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9114-4365","authenticated-orcid":false,"given":"Kanupriya","family":"Whig","sequence":"additional","affiliation":[{"name":"6Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7890-8815","authenticated-orcid":false,"given":"David C.","family":"Schultz","sequence":"additional","affiliation":[{"name":"6Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-6610","authenticated-orcid":false,"given":"Sara","family":"Cherry","sequence":"additional","affiliation":[{"name":"7Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4736-187X","authenticated-orcid":false,"given":"James","family":"Gerson","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1372-7482","authenticated-orcid":false,"given":"Patrizia","family":"Porazzi","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"1Division of Hematology\/Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania."},{"name":"4Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"2025121006473501600_bib1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s41591-021-01436-0","article-title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B-cell malignancies: a phase 1 trial","volume":"27","author":"Spiegel","year":"2021","journal-title":"Nat Med"},{"key":"2025121006473501600_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"2025121006473501600_bib3","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1517\/14712598.2015.1009888","article-title":"How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia","volume":"15","author":"Ruella","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"2025121006473501600_bib5","doi-asserted-by":"crossref","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor\u2013modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025121006473501600_bib6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","article-title":"The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19","volume":"22","author":"Braendstrup","year":"2020","journal-title":"Cytotherapy"},{"key":"2025121006473501600_bib8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet North Am Ed"},{"key":"2025121006473501600_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2020.00888","article-title":"The advent of CAR T-cell therapy for lymphoproliferative neoplasms: integrating research into clinical practice","volume":"11","author":"Cerrano","year":"2020","journal-title":"Front Immunol"},{"key":"2025121006473501600_bib13","first-page":"(suppl; abstr 3025)","article-title":"Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19)","volume":"2017","author":"Galon","year":"35:15","journal-title":"J Clin Oncol"},{"key":"2025121006473501600_bib14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"2025121006473501600_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-Axi-Cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"key":"2025121006473501600_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.17191","article-title":"CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before","volume":"193","author":"Ghilardi","year":"2021","journal-title":"Br J Haematol"},{"key":"2025121006473501600_bib17","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","article-title":"Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction","volume":"10","author":"Singh","year":"2020","journal-title":"Cancer Discov"},{"key":"2025121006473501600_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for fas-mediated off-target tumor killing in T-cell immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov"},{"key":"2025121006473501600_bib19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/cdd.2015.50","article-title":"The BCL-2 protein family, BH3-mimetics and cancer therapy","volume":"22","author":"Delbridge","year":"2015","journal-title":"Cell Death Differ"},{"key":"2025121006473501600_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","article-title":"Bcl-2 antiapoptotic family proteins and chemoresistance in cancer","volume":"137","author":"Maji","year":"2018","journal-title":"Adv Cancer Res"},{"key":"2025121006473501600_bib21","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"2025121006473501600_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJM198701083160204","article-title":"Multiple recurrent genomic defects in follicular lymphoma: a possible model for cancer","volume":"316","author":"Yunis","year":"1987","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM198711053171904","article-title":"Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas","volume":"317","author":"Weiss","year":"1987","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/00001622-199309000-00002","article-title":"Biologic and molecular characterization of non-Hodgkin's lymphoma","volume":"5","author":"Gaidano","year":"1993","journal-title":"Curr Opin Oncol"},{"key":"2025121006473501600_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025121006473501600_bib26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"2025121006473501600_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025121006473501600_bib28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025121006473501600_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"2025121006473501600_bib30","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat Med"},{"key":"2025121006473501600_bib31","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib32","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"key":"2025121006473501600_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121006473501600_bib34","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1073\/pnas.91.9.3700","article-title":"Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia","volume":"91","author":"Nakayama","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025121006473501600_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0092-8674(93)80065-M","article-title":"Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair","volume":"75","author":"Veis","year":"1993","journal-title":"Cell"},{"key":"2025121006473501600_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"key":"2025121006473501600_bib37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/2326-6066.CIR-18-0428","article-title":"Antagonism of IAPs enhances CAR T-cell efficacy","volume":"7","author":"Michie","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"2025121006473501600_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.beha.2018.09.002","article-title":"Progress and predictions: AML in 2018","volume":"31","author":"Rowe","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025121006473501600_bib39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"key":"2025121006473501600_bib40","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fonc.2020.00697","article-title":"CAR T cells for acute myeloid leukemia: state of the art and future directions","volume":"10","author":"Mardiana","year":"2020","journal-title":"Front Oncol"},{"key":"2025121006473501600_bib41","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2014.11.013","article-title":"CD33 directed chimeric antigen receptor T cell therapy as a novel preparative regimen prior to allogeneic stem cell transplantation in acute myeloid leukemia","volume":"21","author":"Kenderian","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025121006473501600_bib42","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"2025121006473501600_bib43","doi-asserted-by":"crossref","first-page":"674.16","DOI":"10.1096\/fasebj.2019.33.1_supplement.674.16","article-title":"Venetoclax, a novel BCL-2 inhibitor, induces cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells","volume":"33","author":"Korashy","year":"2019","journal-title":"FASEB J"},{"key":"2025121006473501600_bib44","doi-asserted-by":"crossref","first-page":"212574","DOI":"10.7573\/dic.212574","article-title":"Venetoclax: evidence to date and clinical potential","volume":"8","author":"Ju\u00e1rez-Salcedo","year":"2019","journal-title":"Drugs Context"},{"key":"2025121006473501600_bib45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/cancers12040938","article-title":"BCL-2 proteins in pathogenesis and therapy of B-cell non-Hodgkin lymphomas","volume":"12","author":"Klanova","year":"2020","journal-title":"Cancers"},{"key":"2025121006473501600_bib46","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2025121006473501600_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat Commun"},{"key":"2025121006473501600_bib48","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"key":"2025121006473501600_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"key":"2025121006473501600_bib50","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"key":"2025121006473501600_bib51","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.4049\/jimmunol.164.8.3950","article-title":"Cutting edge: increased expression of Bcl-2 in antigen-specific memory CD8+ T cells","volume":"164","author":"Grayson","year":"2000","journal-title":"J Immunol"},{"key":"2025121006473501600_bib52","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/0008-5472.CAN-04-2006","article-title":"Bcl-2 overexpression enhances tumor-specific T-cell survival","volume":"65","author":"Charo","year":"2005","journal-title":"Cancer Res"},{"key":"2025121006473501600_bib53","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0092-8674(00)80289-5","article-title":"Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor\u2013deficient mice but not in mutant rag-1\u2212\/\u2212 mice","volume":"89","author":"Maraskovsky","year":"1997","journal-title":"Cell"},{"key":"2025121006473501600_bib54","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib55","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood.V86.4.1255.bloodjournal8641255","article-title":"Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice","volume":"86","author":"Linette","year":"1995","journal-title":"Blood"},{"key":"2025121006473501600_bib56","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1172\/JCI84813","article-title":"Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia","volume":"126","author":"Paszkiewicz","year":"2016","journal-title":"J Clin Invest"},{"key":"2025121006473501600_bib57","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.24064","article-title":"Tumor resistance to apoptosis","volume":"124","author":"Fulda","year":"2009","journal-title":"Int J Cancer"},{"key":"2025121006473501600_bib58","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/sj.onc.1205258","article-title":"Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression","volume":"21","author":"Fulda","year":"2002","journal-title":"Oncogene"},{"key":"2025121006473501600_bib59","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.tranon.2018.07.012","article-title":"Immunogenomics analysis reveals that TP53 mutations inhibit tumor immunity in gastric cancer","volume":"11","author":"Jiang","year":"2018","journal-title":"Translational oncology"},{"key":"2025121006473501600_bib60","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/sj.bjc.6603359","article-title":"Absence of Bcl-2 and Fas\/CD95\/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma","volume":"95","author":"Maruyama","year":"2006","journal-title":"Br J Cancer"},{"key":"2025121006473501600_bib61","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/cgt.2013.35","article-title":"Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy","volume":"20","author":"Karlsson","year":"2013","journal-title":"Cancer Gene Ther"},{"key":"2025121006473501600_bib62","doi-asserted-by":"crossref","first-page":"608167","DOI":"10.3389\/fimmu.2020.608167","article-title":"Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells","volume":"11","author":"Yang","year":"2020","journal-title":"Front Immunol"},{"key":"2025121006473501600_bib63","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"key":"2025121006473501600_bib64","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.4049\/jimmunol.155.5.2311","article-title":"Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal","volume":"155","author":"Broome","year":"1995","journal-title":"J Immunol"},{"key":"2025121006473501600_bib65","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","article-title":"Clinical predictors of venetoclax pharmacokinetics in chronic lymphocytic leukemia and non-Hodgkin's lymphoma patients: a pooled population pharmacokinetic analysis","volume":"18","author":"Jones","year":"2016","journal-title":"AAPS J"},{"key":"2025121006473501600_bib66","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrd3847","article-title":"Vemurafenib: the first drug approved for BRAF-mutant cancer","volume":"11","author":"Bollag","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"2025121006473501600_bib67","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025121006473501600_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol Cancer"},{"key":"2025121006473501600_bib69","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/cancers13020197","article-title":"Bcl-2 enhances chimeric antigen receptor T cell persistence by reducing activation-induced apoptosis","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"2025121006473501600_bib70","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1074-7613(02)00322-9","article-title":"Activated T cell death in vivo mediated by proapoptotic Bcl-2 family member bim","volume":"16","author":"Hildeman","year":"2002","journal-title":"Immunity"},{"key":"2025121006473501600_bib71","doi-asserted-by":"crossref","first-page":"594609","DOI":"10.3389\/fimmu.2020.594609","article-title":"Cytokine and chemokine signals of T-cell exclusion in tumors","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2025121006473501600_bib72","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2014how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"2025121006473501600_bib73","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"key":"2025121006473501600_bib74","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"2025121006473501600_bib75","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL-2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"2025121006473501600_bib76","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood.V92.9.3152","article-title":"Clinical relevance of BCL-2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma","volume":"92","author":"Kramer","year":"1998","journal-title":"Blood"},{"key":"2025121006473501600_bib77","doi-asserted-by":"crossref","first-page":"3059\u201368","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025121006473501600_bib78","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025121006473501600_bib79","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"2025121006473501600_bib80","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/bioinformatics\/btu684","article-title":"DOSE: an R\/Bioconductor package for disease ontology semantic and enrichment analysis","volume":"31","author":"Yu","year":"2015","journal-title":"Bioinformatics"},{"key":"2025121006473501600_bib81","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-21-1026\/3184397\/cd-21-1026.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/doi\/10.1158\/2159-8290.CD-21-1026\/3209057\/cd-21-1026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/12\/10\/2372\/3211320\/2372.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/12\/10\/2372\/3211320\/2372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:47:52Z","timestamp":1765367272000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/12\/10\/2372\/709421\/Modulation-of-BCL-2-in-Both-T-Cells-and-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":81,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,7,29]]},"published-print":{"date-parts":[[2022,10,5]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-21-1026","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.c.6549622","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22541380.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6549622.v1","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2159-8290.22541380","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]}}}